Shared Resource Core C. Administration. Darell D. Bigner, M.D., Ph.D., Core Director Support is requested for an Administrative Core including effort for Dr. Darell Bigner as P01 Program Director and Principal Investigator and Director of the Administrative Core. Dr. Bigner will provide oversight of the scientific and administrative activities of the program project grant. Dr. Bigner will chair the P01 Executive Committee which includes all research project leaders and shared resource core directors (Drs. Michael Zaiutsky, John Sampson, James Vredenburgh, and Daniel Barboriak). Together they will foster communication and collaboration between the research projects and shared resource cores and monitor and assess progress. Dr. Bigner will meet weekly with research project leaders and shared resource core directors, and he and his staff will serve as the editorial review/clearinghouse for all publications resulting from P01 activities. Dr. Bigner will plan and coordinate regular seminars which will include the P01 project leaders, core directors and investigators. These seminars will be a part of the monthly Neuro-Oncology Program Seminar Series coordinated by Dr. Bigner. Dr. Bigner will coordinate the participation of P01 investigators in national and international workshops, conferences, and meetings on brain tumor research. Also he will coordinate all the activities of the P01Internal and External Advisory Committees and will serve as the P01 liaison with other appropriate academic units within Duke University and with outside entities. Core support is requested for a Staff Specialist who will be responsible for scheduling all internal and external meetings, budgetary monitoring, and general administrative assistance. Core C will provide administrative support for all three research projects and the two shared resource cores.
The Administrative Core is necessary to coordinate all the scientific and administrative activities in the program project grant, all of which are designed to develop new, innovative, more effective, and less toxic treatments for CNS tumors.
|Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2015) D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. Nucl Med Biol 42:19-27|
|Koumarianou, Eftychia; Slastnikova, Tatiana A; Pruszynski, Marek et al. (2014) Radiolabeling and in vitro evaluation of (67)Ga-NOTA-modular nanotransporter--a potential Auger electron emitting EGFR-targeted radiotherapeutic. Nucl Med Biol 41:441-9|
|Killela, Patrick J; Pirozzi, Christopher J; Healy, Patrick et al. (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515-25|
|Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2014) Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 55:650-6|
|Choi, Jaeyeon; Vaidyanathan, Ganesan; Koumarianou, Eftychia et al. (2014) N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. Nucl Med Biol 41:802-12|
|Congdon, Kendra L; Gedeon, Patrick C; Suryadevara, Carter M et al. (2014) Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol 16 Suppl 8:viii20-5|
|Choi, Bryan D; Gedeon, Patrick C; Kuan, Chien-Tsun et al. (2013) Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. J Immunol Methods 395:14-20|
|Choi, Bryan D; Kuan, Chien-Tsun; Cai, Mingqing et al. (2013) Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci U S A 110:270-5|
|Yang, Shicheng; Archer, Gary E; Flores, Catherine E et al. (2013) A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. Cancer Immunol Immunother 62:1649-62|
|Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2013) Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol 40:52-9|
Showing the most recent 10 out of 11 publications